Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Aug 4, 2019
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a single center, pilot study to evaluate critically ill patients diagnosed with acute pulmonary embolism using endobronchial ultrasound (EBUS). The investigators anticipate to enroll 20 subjects at Ronald Reagan UCLA Medical Center and UCLA Medical Center, Santa Monica. The enrolled subjects will be imaged using the flexible bronchoscopy with EBUS.
After informed consent is obtained, the following procedure will be performed:
An Olympus EBUS bronchoscope will be used for all endobronchial ultrasound examinations. This scope has a 6.9 mm outer diameter, a 2.7 mm working channel and...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥ 18 years of age.
- • The patient or patient's surrogate must understand and sign informed consent form (ICF).
- • Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.
- Exclusion Criteria:
- • Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
- • Endotracheal tube size less than 8.0 mm.
- • Contraindications to lidocaine.
- Pulmonary Vascular Mapping Substudy:
- Enrollment for the pulmonary vascular mapping substudy will be based on the following inclusion and exclusion criteria:
- Inclusion criteria:
- • Patient ≥ 18 years of age.
- • The patient or patient's surrogate must understand and sign informed consent form (ICF).
- • Intubated patients undergoing clinical bronchoscopy, as determined by the treating physician.
- Exclusion criteria:
- • Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
- • Endotracheal tube size less than 8.0 mm.
- • Contraindications to lidocaine.
- Retrospective Chart Review:
- • Of the 60 total subjects enrolled in the study, media including images and videos that are previously recorded for 20 patients who underwent a clinical bronchoscopy with EBUS as a part of their standard of care will also be available to our research team without consent from the patient to help supplement the data we obtain from the 20 subjects that are enrolled in the pulmonary vascular mapping substudy.
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Santa Monica, California, United States
Patients applied
Trial Officials
Colleen L Channick, M.D.
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials